Fig. 2 | The Journal of Antibiotics

Fig. 2

From: In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens

Fig. 2

Efficacy of GT-1 and GT-1/GT-055 in Y. pestis challenge study. Mice infected with 110X LD50 of Y. pestis strain CO92. Treatment with saline (negative control), ciprofloxacin (30 mg kg−1, q12h), and GT-1 (q6h) or GT-1/GT-55 (q6h) at one of the three specified doses was initiated at 6 h post-infection and continued for 7 days (n = 10/group). Survival was monitored for 30 days

Back to article page